Tenosynovitis Clinical Trial
Official title:
The Natural History of Congenital Trigger Thumbs
This will be a prospective study of all children ages 0 - 5 years old at the time of entry into the study that meet the inclusion criteria who present with congenital trigger thumb. Patient records will be reviewed for eligibility before obtaining parental permission. They will be enrolled in the study at their first visit and followed every year for up to 4 years or until one of the exclusion criteria are met. Participating sites include the University of Utah Orthopaedic Center, Primary Children's Medical Center and Shriners Hospital for Children.
Trigger thumb is a stenosis tenosynovitis of the flexor pollicis longus tendon of the thumb1. The eitiology of congenital trigger thumb is unclear with many authors proposing both hereditary and acquired causes2-4. Surgical release of congenital trigger thumbs has been recommended as definitive treatment, though controversy exists over the natural history of congenital trigger thumbs5-8. There have been a number of studies looking at the natural history of congenital trigger thumbs with spontaneous resolution rates ranging from 0-96% over a median duration of follow up that ranged from 6 months to 48 months9-14. Based on our clinical experience, the investigators do not feel that congenital trigger thumbs resolve spontaneously and that definitive treatment requires surgical release. However, the investigators need to do further scientific research into the natural history of trigger thumbs to determine how often trigger thumb resolves without needing surgical intervention. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03704584 -
Corticosteroid(CS) + Lido or Corticosteroid(CS) Alone
|
Phase 4 | |
Recruiting |
NCT02320929 -
The Treatment of Purulent Flexor Tenosynovitis
|
N/A | |
Completed |
NCT03792945 -
Comparison of the Efficacy of Corticosteroid Injection and ESWT in Patients With CTS
|
Phase 4 | |
Terminated |
NCT02266433 -
Dexamethasone Versus Ketorolac Injection for the Treatment of Local Inflammatory Hand and Upper Extremity Disorders
|
Phase 3 | |
Completed |
NCT03914235 -
Anesthesia Tumescent for Surgical Management of Tenosynovitis.
|
N/A |